Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharma (NQ: AMPH )

45.46 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharma

< Previous 1 2 3 4 5 6 7 Next >
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024
Via ACCESSWIRE
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January. 
Via Investor's Business Daily
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. 
Via Benzinga
Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024
Via ACCESSWIRE
Why the growth investor may take a look at NASDAQ:AMPH.
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
Exploring NASDAQ:AMPH's growth characteristics.
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations 
Via Chartmill
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Beats Revenue for Q2 2024
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024
Via ACCESSWIRE
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts
These 2 small cap healthcare stocks could boom on a new sector breakout, Wall Street analysts see up to double-digit upside in each 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
Via ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
Via ACCESSWIRE
NASDAQ:AMPH, an undervalued stock with good fundamentals.
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH): good value for what you're paying. 
Via Chartmill
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Via ACCESSWIRE
Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
Via ACCESSWIRE
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference
Via ACCESSWIRE
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Delving into NASDAQ:AMPH's Growth Prospects.
Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing? 
Via Chartmill
Earnings Outlook For Amphastar Pharma
Via Benzinga
Is NASDAQ:AMPH a Fit for Growth Investing Strategies?
Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? 
Via Chartmill
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024
Via ACCESSWIRE
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies
Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections... 
Via Benzinga
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.